Clinical Trial Update: Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after autologous stem cell transplant failure or ineligible s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lymphoma. Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2017-05-30